DNAtrix, Inc.

DNAtrix is a privately held, clinical stage, biotechnology company developing virus-driven immunotherapies for cancer

[DNAtrix, Inc. @DNAtrixInc]

We thank SNO for the opportunity to present our positive overall survival data in DIPG, a rapidly progressing brain tumor with the worst prognosis of any pediatric cancer. https://t.co/uXzpezwjaX

[DNAtrix, Inc. @DNAtrixInc]

Join us as we welcome industry veteran, David Liebowitz, M.D., Ph.D., as Chief Medical Officer! Dave brings over 20 years of experience in oncology drug and viral vaccine development. https://t.co/REAClZ2fXV #biotechnology #lifesciences

[DNAtrix, Inc. @DNAtrixInc]

This September we #GoGold as we raise awareness and recognize those children affected by cancer. At DNAtrix, we are tackling pediatric DIPG, a highly aggressive brain tumor with no approved therapies. Learn more ways to get involved: https://t.co/cUgEVlHMH8 #CCAM

[DNAtrix, Inc. @DNAtrixInc]

Glioblastoma (GBM) is one of the most complex, treatment-resistant, and deadliest types of cancers. This Wednesday, the National Brain Tumor Society is hosting a virtual event to raise awareness about GBM. #GBMDay on July 21. https://t.co/WnGwJrIRRJ

[DNAtrix, Inc. @DNAtrixInc]

Join the webcast to hear Jeff Knapp, CEO, and Brett Ewald, Ph.D., SVP of Development & Corporate Strategy, present at the Raymond James Conference on June 21 at 1:20pm ET. https://t.co/FyrD48q4aW

[DNAtrix, Inc. @DNAtrixInc]

May 27th is National Day of Gray when we recognize patients with brain tumors, as well as acknowledge the efforts of caregivers and volunteers who have supported the community. #BTAM #GoGrayinMay #GrayMay #TheGrayscale https://t.co/lIeiUD5jd4

[DNAtrix, Inc. @DNAtrixInc]

DNAtrix’s SVP of Development & Corporate Strategy, Dr. Brett Ewald, discusses the therapeutic potential of oncolytic viruses at the World Medical Innovation Forum: https://t.co/SYX86vF5Zn

[DNAtrix, Inc. @DNAtrixInc]

All throughout May, @NBTStweets will be sponsoring events to help increase funding for medical research and treatment development, expand access to care & improve the quality of life for people with brain tumors. Learn how to participate during #GrayMay: https://t.co/MGSmuXlxwN

[DNAtrix, Inc. @DNAtrixInc]

We are excited to have begun a Phase 1 study with our second drug candidate. DNX-2440 is an immunotherapy that expresses OX40 ligand, which is expected to enhance the anti-tumor immune response. https://t.co/rkFC567ODq

[DNAtrix, Inc. @DNAtrixInc]

Join us as we welcome the newest member of our Board of Directors, Herb Cross, CFO of Atreca. Herb brings over 20 years of experience in executive leadership and strategic financial management. We look forward to his contributions to DNAtrix. https://t.co/8xOfI9umwm

[DNAtrix, Inc. @DNAtrixInc]

We are proud to announce that promising preclinical data with DNX-2401 against two devastating pediatric tumors -- AT/RT and CNS-PNET -- was published in Clinical Cancer Research. Read the Press Release here: https://t.co/n15JeVJcFT

[DNAtrix, Inc. @DNAtrixInc]

Dr. Zadeh presented late-breaking Phase 2 data with DNX-2401 in recurrent glioblastoma at a plenary session at SNO. We are hopeful these positive data may translate into a new therapy for these patients. Read about our results: https://t.co/pLbYsCcCn9

[DNAtrix, Inc. @DNAtrixInc]

Follow our multiple upcoming data presentations, including late-breaking Phase 2 CAPTIVE data in recurrent GBM, at the SNO Annual Meeting from Nov 19-21. Read more: https://t.co/PofF9tjNFh

[DNAtrix, Inc. @DNAtrixInc]

DNAtrix is pleased to welcome Jeff Knapp as CEO and to our Board of Directors.
https://t.co/XHRlzipqf1

[DNAtrix, Inc. @DNAtrixInc]

Data from the Phase 2 CAPTIVE / KEYNOTE-192 study demonstrate that #DNX2401 (#tasadenoturev) with pembrolizumab elicits durable clinical activity and has a favorable safety profile for patients with recurrent #glioblastoma

https://t.co/NF4VHH78XI

[DNAtrix, Inc. @DNAtrixInc]

Development and clinical studies of oncolytic adenovirus #DNX2401 highlighted in Dr. Fred Lang’s talk, “Principles of Viral Therapies Against Gliomas - Oncolytic and Immunological Aspects” #sno2019 @NeuroOnc @TMCInnovation @JLABS

[DNAtrix, Inc. @DNAtrixInc]

Presentation by Dr. Gomez-Manzano highlights DNAtrix #oncolyticvirus technology expressing an immune modulator and reviews development of #DNX2401. Results from 3 active clinical trials to be presented at #sno2019 @NeuroOnc

[DNAtrix, Inc. @DNAtrixInc]

In addition to an update on the Phase 2 CAPTIVE / KEYNOTE-192 trial, DNAtrix’s #oncolyticvirus technology will be highlighted across six additional abstracts selected for presentation https://t.co/JpkqDYPfC5 #SNO2019 @NeuroOnc @TMCInnovation @JLABS

[DNAtrix, Inc. @DNAtrixInc]

Updated results from the Phase 2 CAPTIVE / KEYNOTE-192 study of the #oncolyticvirus #DNX2401 with pembrolizumab for recurrent glioblastoma at the 2019 SNO Annual Meeting.
Presentation (ATIM-33) will be given by Dr. Clark Chen, Sunday am #SNO2019 @NeuroOnc @TMCInnovation @JLABS

[DNAtrix, Inc. @DNAtrixInc]

The first patient has been treated with our next generation virus #DNX2440 (expressing immune stimulator OX40 ligand) in a trial for recurrent #glioblastoma #oncolyticvirus @ClinicaNavarra @AlcyoneLS https://t.co/stkioHUNcQ